SONN Utang jangka cendhak perusahaan Sonnet BioTherapeutics Holdings

sonnetbio.com - logo grafis emiten SONN

Sonnet BioTherapeutics (SONN) retains its immuno-oncology expert staff through stock options, having optimized its team. Changes in short-term liabilities illustrate borrowing dynamics, with the parameter stabilizing at 0.00. The laboratory develops targeted immunomodulators to combat metastases. However, management's high reliance on external funding and binary risks make pipeline development critically dependent on successful fundraising.

SONN Utang jangka cendhak Sonnet BioTherapeutics Holdings Inc. (04.07.2022 - 13.12.2025)

Rincian analitis lan laporan data perusahaan Sonnet BioTherapeutics Holdings, Inc. (SONN)

- kuotasi saiki lan rata-rata prakiraan nilai:
Bagan rega Sonnet BioTherapeutics Holdings Inc.|SONN - Rata-rata rega prakiraan
- data kapitalisasi pasar:
Nilai pasar Sonnet BioTherapeutics Holdings|SONN - Nilai Total Perusahaan
- data nilai buku modal saham:
Aset Bersih saben Siji Saham Sonnet BioTherapeutics|SONN - Ekuitas Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku sonnetbio.com|SONN - Aset Neraca Perusahaan
- indikator total utang lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas Sonnet BioTherapeutics|SONN - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Sonnet BioTherapeutics Holdings Inc.|SONN - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Sonnet BioTherapeutics Holdings|SONN - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Sonnet BioTherapeutics|Likuiditas cepet sonnetbio.com
- data bathi lan kelipatan valuasi:
SONN - Penghasilan resik
Analisis umum perusahaan:sonnetbio.com (SONN)
Barang unggulan Sonnet BioTherapeutics

Investment analysis of Sonnet BioTherapeutics (SONN) requires a precise liquidity assessment, where the company's short-term liabilities reflect the volume of loans maturing within one year. This indicator allows for an evaluation of interest overpayment risks when scaling production via CDMO partners, confirming the efficiency of utilizing external capacities in New Jersey to optimize capital structure and minimize debt load.

Pesaing Sonnet BioTherapeutics

IBRX - Utang jangka cendhak perusahaan|Utang jangka cendhak Immunocore Holdings|Janux Pharma (JANX) - Utang jangka cendhak perusahaan|RCUS (Arcus Corp) - Utang jangka cendhak perusahaan|Utang jangka cendhak perusahaan Zymeworks Inc.|Utang jangka cendhak tangotx.com TNGX|Utang jangka cendhak perusahaan IOVA|Immatics NV (IMTX) - Tanggungan jangka cendhak|Xencor Corp - Kewajiban jangka cendhak perusahaan|Compass Therapeutics Corp (CMPX) - Utang jangka cendhak|REPL: Kewajiban jangka cendhak perusahaan|Silihan lan utang jangka cendhak perusahaan LYEL (lyell.com)|IPHA: Utang jangka cendhak perusahaan|PYXS - Gunggunge utang jangka cendhak|Utang jangka cendhak perusahaan Compugen Ltd|Kewajiban jangka cendhak perusahaan IO Biotech Inc. (IOBT)|Utang jangka cendhak perusahaan Sutro Biopharma, Inc. (STRO)|Kewajiban jangka cendhak perusahaan minktherapeutics.com INKT|Werewolf Therapeutics, Inc. - Kewajiban jangka cendhak perusahaan|Utang jangka cendhak perusahaan Immix Biopharma Inc. IMMX|ALXO - Utang jangka cendhak perusahaan|CUE (Cue Biopharma Inc.) - Tanggungan utang jangka cendhak perusahaan|pdsbiotech.com (PDSB) - Utang jangka cendhak perusahaan|Utang jangka cendhak MAIABiotech.com (MAIA)|Kewajiban jangka cendhak perusahaan LIMN|LVTX - Tanggungan jangka cendhak|Kewajiban jangka cendhak perusahaan NXTC (NextCure Corp)|Gedhene kewajiban jangka cendhak LPTX|Utang jangka cendhak perusahaan INTS (Intensity Therapeutics, Inc.)|Silihan lan utang jangka cendhak perusahaan SNSE|Theriva Biologics - Utang jangka cendhak perusahaan|Utang jangka cendhak Gritstone bio, Inc.|Kineta Bio (KA) - Utang jangka cendhak perusahaan|NexImmune Corporation - Silihan lan utang jangka cendhak perusahaan|TSBX (Turnstone Biologics Corp) - Utang jangka cendhak perusahaan|Utang jangka cendhak perusahaan vaccinex.com|Utang jangka cendhak perusahaan Harpoon Therapeutics, Inc. (HARP)